The latest biotech news

News and Trends 29 Jun 2023

FDA gives Orphan Drug Designation to CellCentric multiple myeloma drug

CellCentric, a UK-based biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inobrodib in the treatment of multiple myeloma. Delivered as an oral capsule, inobrodib can be used at home without requiring intensive monitoring. It is a first-in-class drug, with a new mechanism of action. It […]

June 29, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 29 Jun 2023

AI program finds multiple influenza drug targets

Poolbeg Pharma, a clinical-stage biopharma company focusing on infectious and other prevalent diseases, has announced a breakthrough in its world-first influenza Artificial Intelligence (AI) Programme working with the company CytoReason. Poolbeg’s disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analyzed using CytoReason’s AI-led platform. The […]

June 29, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 29 Jun 2023

Centogene and Lifera to form Saudi Arabian Joint Venture

Centogene N.V. and Lifera have announced a strategic collaboration with the formation of a joint venture (JV) to increase local and regional access and rapid delivery of multiomic testing to patients in Saudi Arabia and countries of the Gulf Cooperation Council (GCC). Under the terms of the collaboration, Centogene will receive a $30 million mandatory […]

June 29, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 29 Jun 2023

Vesalius Biocapital to invest €95M in life science companies

Vesalius Biocapital, a Luxembourg-based life sciences venture capital investor, has announced the first close of its fourth fund, Vesalius Biocapital IV, securing more than €95 million ($103.7 million) of commitments. The fund has attracted investors including the European Investment Fund (EIF). Starting immediately Vesalius Biocapital IV is to invest in first and best-in-class European life […]

June 29, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Jun 2023

Small particles will deliver TB drugs to the lungs in the future

Treatment of the dangerous infectious disease tuberculosis faces the challenge of pathogens frequently being resistant to several common antibiotics. Researchers at Karlsruhe Institute of Technology (KIT) in Germany have developed nanoparticles to deliver new antibiotics directly to the lungs in the future. Surfactants ensure that the highly fat-soluble antibiotics disperse very finely in water and […]

June 28, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 28 Jun 2023

New platform cuts time engineering and selecting genome editors

A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has developed a new way to break through the current limited throughput in optimizing precise genome editors at scale, engineer hundreds of base editor variants in parallel instead of current one-by-one testing, and informing users of the most suitable ones […]

June 28, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 27 Jun 2023

UCB myasthenia gravis drug given FDA approval

UCB has announced RYSTIGGO (rozanolixizumab-noli) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. Rozanolixizumab-noli injection for subcutaneous infusion is a humanized IgG4 monoclonal antibody that binds to the neonatal […]

June 27, 2023 - 5 minutesmins - By Jim Cornall

Neisseria gonorrhoeae gonorrhoea gonorrhea

News and Trends 27 Jun 2023

GSK gonorrhea vaccine fast tracked

The US Food and Drug Administration (FDA) has granted a Fast Track designation for GSK plc’s Neisseria gonorrhoeae investigational vaccine (NgG). The vaccine candidate is currently in an ongoing phase II trial and aims to demonstrate proof of concept by assessing the efficacy of the NgG vaccine in healthy adults, 18 to 50 years of […]

June 27, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 27 Jun 2023

Astraveus exits stealth to advance cell and gene therapy platform

Astraveus SAS has emerged from stealth with the completion of an oversubscribed €16.5 million ($18.1 million) Series Seed financing. The company creates modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing. Astraveus has developed the Lakhesys platform, an end-to-end cell foundry that uses deep process optimization and single-use, microfluidic bioprocessors to deliver […]

June 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jun 2023

Actimed Therapeutics raises £5M to advance lead program for cancer cachexia

Actimed Therapeutics Ltd, a U.K.-based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, has raised more than £5 million ($6.4 million) in an over-subscribed Series A financing round. The investment will support the development of the Actimed pipeline, including S-pindolol benzoate, with preparations […]

June 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jun 2023

Laying the foundation for the future of personalized treatment?

In the evolving world of precision medicine, the need for methods that can measure biomolecules with supreme accuracy and specificity is paramount. Recognizing this, Yan Xu of the Graduate School of Engineering at Osaka Metropolitan University in Japan, and his international research team, say they have made a great stride in this direction. They have […]

June 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 26 Jun 2023

AbbVie takes step forward in Europe with migraine drug

AbbVie says the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CMHP) has adopted a positive opinion recommending the approval of atogepant for the prophylaxis of migraine in adults who have four or more migraine days per month. If approved, AbbVie will be the only company to offer a once daily oral […]

June 26, 2023 - 4 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

FDA gives Orphan Drug Designation to CellCentric multiple myeloma drug

AI program finds multiple influenza drug targets

Centogene and Lifera to form Saudi Arabian Joint Venture

Vesalius Biocapital to invest €95M in life science companies

Small particles will deliver TB drugs to the lungs in the future

New platform cuts time engineering and selecting genome editors

UCB myasthenia gravis drug given FDA approval

GSK gonorrhea vaccine fast tracked

Astraveus exits stealth to advance cell and gene therapy platform

Actimed Therapeutics raises £5M to advance lead program for cancer cachexia

Laying the foundation for the future of personalized treatment?

AbbVie takes step forward in Europe with migraine drug

Subscribe to our newsletter to get the latest biotech news!